Xia, Zhongjun
108  Ergebnisse:
?
2

P949: COMBINATION GA AND MPR VULNERABILITY SCORING TOOLS EF..:

Lu, Minqiu ; Peng, Liu ; Zhuang, Junling...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431282/.  , 2023
 
?
 
?
4

Targeting P21-activated kinase suppresses proliferation and..:

Su, Ning ; Fang, Yu ; Chen, Xu...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629744/.  , 2023
 
?
5

Aponermin or placebo in combination with thalidomide and de..:

Xia, Zhongjun ; Leng, Yun ; Fang, Baijun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576321/.  , 2023
 
?
6

Ibrutinib as monotherapy versus combination therapy in Chin..:

Zhang, Yuchen ; Liu, Panpan ; Cai, Jun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678091/.  , 2022
 
?
 
?
 
?
 
?
 
?
11

A nomogram prognostic index for risk-stratification in diff..:

Cai, Jun ; Tian, Xiaopeng ; Ma, Shuyun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329293/.  , 2021
 
?
12

Sequential P‐GEMOX and radiotherapy for early‐stage extrano..:

Zhang, Yuchen ; Ma, Shuyun ; Cai, Jun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291061/.  , 2021
 
?
13

A Preliminary Study of Culture Shock and Adaptation Tactics..:

Xia, Zhongjun
http://www.academypublication.com/ojs/index.php/tpls/article/view/tpls1003336341/2271.  , 2020
 
?
14

Ixazomib-based frontline therapy in patients with newly dia..:

Li, Jing ; Bao, Li ; Xia, Zhongjun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474576/.  , 2020
 
?
 
1-15